Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
These data demonstrate that the prometastatic role of galectin-3 is regulated by its ability to bind to the tumor cell surface and highlight the potential of monitoring ST6GalNAc2 expression to stratify patients with breast cancer for treatment with galectin-3 inhibitors.
|
24520024 |
2014 |
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Sticking to sugars at the metastatic site: sialyltransferase ST6GalNAc2 acts as a breast cancer metastasis suppressor.
|
24596201 |
2014 |
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
ST6GalNAcII elucidated the unusual properties of invasion in breast cancer cell via modulating the PI3K/AKt signaling pathway.
|
24756995 |
2014 |
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In particular, we observed an enrichment of mutations in genes (B3GNT2, B4GALT2, ST6GALNAC2) involved in the biosynthesis of N- and Cores 1-3 O-linked glycans in the colon, accounting for ~16% of the CRCs tested.
|
27004849 |
2016 |
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
We measured the levels of miR-182, miR-135b, and ST6GALNAC2 in a series of CRC cell lines and tissues using real-time PCR.
|
29030743 |
2017 |
Colorectal Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Suppression of these miRNAs implicated an inverse function, while altered expression of ST6GALNAC2 mediated CRC progression upon transfection with miR-135b/-182 mimic or inhibitor.
|
28767179 |
2017 |
Follicular thyroid carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Using real-time PCR, western blot and IHC analysis, ST6GalNAcII differed in three follicular thyroid cancer cell lines (FTC133, primary and FTC238, lung metastasis).
|
26820593 |
2016 |
IGA Glomerulonephritis
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that potential genetic interactions of C1GALT1 and ST6GALNAC2 variants influence IgA1 O-glycosylation, disease predisposition, and disease severity, and may contribute to the polygenic nature of IgAN.
|
19357720 |
2009 |
IGA Glomerulonephritis
|
0.330 |
Biomarker
|
disease |
CTD_human |
Our results demonstrated that the frequency of haplotype ADG in the promoter region of ST6GALNAC2 was significantly higher in IgAN patients than that in controls (p=0.0069; odds ratio [OR]=1.36; 95% confidence interval [CI], 1.08-1.72).
|
17480010 |
2007 |
IGA Glomerulonephritis
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Our results demonstrated that the frequency of haplotype ADG in the promoter region of ST6GALNAC2 was significantly higher in IgAN patients than that in controls (p=0.0069; odds ratio [OR]=1.36; 95% confidence interval [CI], 1.08-1.72).
|
17480010 |
2007 |
IGA Glomerulonephritis
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Expression of ST6GALNAC2 in B peripheral lymphocytes was significantly lower in patients with IgAN than that in normal controls (3.7 +/- 2.2 versus 6.3 +/- 2.3, P = 0.016); alpha2,6-ST activity in B lymphocytes was correlated positively with the level of alpha2,6-sialic acid in serum IgA1 in patients (n = 42) and controls (n = 12) (r = 0.37, P = 0.007).
|
19170967 |
2009 |
Major Depressive Disorder
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Moreover, the expression of ST6GALNAC2 was decreased in leukocytes from patients with MDD.
|
28844310 |
2018 |
Malignant neoplasm of breast
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Aggressive estrogen receptor-negative breast cancers with reduced ST6GalNAc2 expression alter O-linked glycans on tumor cell surface, increasing soluble lectin galectin-3 binding and tumor cell clustering at metastatic sites.
|
24596201 |
2014 |
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
ST6GalNAcII elucidated the unusual properties of invasion in breast cancer cell via modulating the PI3K/AKt signaling pathway.
|
24756995 |
2014 |
Malignant neoplasm of breast
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
These data demonstrate that the prometastatic role of galectin-3 is regulated by its ability to bind to the tumor cell surface and highlight the potential of monitoring ST6GalNAc2 expression to stratify patients with breast cancer for treatment with galectin-3 inhibitors.
|
24520024 |
2014 |
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
The SIATL1 gene, encoding STM, was mapped to the long arm of human chromosome 17 at q23-qter, a region that is nonrandomly deleted in human breast cancers.
|
11984005 |
2002 |
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
In this issue of Cancer Discovery, Murugaesu and colleagues, using an in vivo functional RNA interference metastasis screen, identified sialyltransferase ST6GalNAc2 as a novel metastasis suppressor gene.
|
24596201 |
2014 |
Mammary Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
However, Southern analyses indicated that SIATL1 is usually not grossly rearranged in breast tumors.
|
11984005 |
2002 |
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In Gal-1-deficient mice, MCAM-silenced (MCAM(KD)) or ST6GalNAc2-overexpressing (ST6(O/E)) melanoma cells exhibited slower growth rates, underscoring a key role for melanoma cell Gal-1 ligands and host Gal-1 in melanoma growth.
|
25756799 |
2015 |
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
The objective of this study is to clarify the possible role and mechanism of ST6GalNAcII in the metastasis process of breast carcinoma.
|
24756995 |
2014 |
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
In this issue of Cancer Discovery, Murugaesu and colleagues, using an in vivo functional RNA interference metastasis screen, identified sialyltransferase ST6GalNAc2 as a novel metastasis suppressor gene.
|
24596201 |
2014 |
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Using this approach, we identified the sialyltransferase ST6GalNAc2 as a novel breast cancer metastasis suppressor.
|
24520024 |
2014 |
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
The present study investigated the alteration in expression of ST6GalNAcII involved in invasion and to clarify the possible mechanism of ST6GalNAcII in the metastasis process in human follicular thyroid carcinoma cell lines.
|
26820593 |
2016 |
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
These data demonstrate that the prometastatic role of galectin-3 is regulated by its ability to bind to the tumor cell surface and highlight the potential of monitoring ST6GalNAc2 expression to stratify patients with breast cancer for treatment with galectin-3 inhibitors.
|
24520024 |
2014 |
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Aggressive estrogen receptor-negative breast cancers with reduced ST6GalNAc2 expression alter O-linked glycans on tumor cell surface, increasing soluble lectin galectin-3 binding and tumor cell clustering at metastatic sites.
|
24596201 |
2014 |